Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ankyra
AddedFeb 17, 2024
UpdatedJun 18, 2026
Ankyra

Ankyra

Ankyra: Innovating localized cytokine-based systemic adaptive immune cancer therapies.

HQ
Boston, MA, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Ankyra is focused on developing innovative cancer therapies using localized cytokines to prime a systemic adaptive immune response. Their core mission is to enhance the safety and efficacy of cytokine immunotherapies by promoting prolonged local immune activation while limiting systemic toxicity. Ankyra's platform aims to improve cancer treatment outcomes by localizing cytokines specifically within tumor tissues, thereby reducing the broad immune activation and associated toxicity seen with systemic dosing.

Ankyra has made significant strides in the field of cancer immunotherapy, leveraging their Anchored Immunotherapy approach to achieve prolonged and targeted immune responses. This novel method has the potential to transform cancer treatment by offering a safer and more effective alternative to current cytokine therapies. The company continues to advance its research and development efforts, contributing to the broader goal of improving cancer patient outcomes through innovative therapeutic solutions.

Ankyra - Similar Companies

AnkyrBio logo

AnkyrBio

ankyrbio.com

Umoja Biopharma logo

Umoja Biopharma

Pionyr Immunotherapeutics logo

Pionyr Immunotherapeutics

Ankasa Regenerative Therapeutics logo

Ankasa Regenerative Therapeutics

Avenge Bio logo

Avenge Bio

avengebio.com

Asher Bio logo

Asher Bio

asherbio.com

Werewolf Therapeutics logo

Werewolf Therapeutics

werewolftx.com

Synthekine logo

Synthekine

synthekine.com

Neoantigenics logo

Neoantigenics

Angarus Therapeutics logo

Angarus Therapeutics

angarustx.com

Anixa Biosciences logo

Anixa Biosciences

anixa.com

Larkspur Biosciences logo

Larkspur Biosciences

larkspur.bio

Mana Therapeutics logo

Mana Therapeutics

Parthenon Therapeutics logo

Parthenon Therapeutics

parthenontx.com

Dorna Therapeutics logo

Dorna Therapeutics

Ankyra - Quick Facts

Who are Ankyra's competitors?

Companies similar to Ankyra include AnkyrBio, Umoja Biopharma, Pionyr Immunotherapeutics and Ankasa Regenerative Therapeutics.

When was Ankyra founded?

Ankyra was founded in 2019.

Where is Ankyra's headquarters located?

Ankyra's headquarters is located in Boston, MA, US.

When was Ankyra's last funding round?

Ankyra's most recent funding round was for $45M (USD) in November 2021.

How much has Ankyra raised to-date?

As of Nov 12, 2021, Ankyra has raised a total of $59.5M (USD).

How many employees does Ankyra have?

Ankyra has 17 employees as of Feb 4, 2024.

Ankyra - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Customer
  • Small Business
Main Product
  • Cancer Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified